Li J, Li H, Run ZC, Wang ZL, Jiang T, An Y, Li Z. RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma. World J Gastrointest Oncol 2022; 14(8): 1574-1584 [PMID: 36160746 DOI: 10.4251/wjgo.v14.i8.1574]
Corresponding Author of This Article
Zhi Li, DA, Chief Doctor, Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, No. 127 Dong Ming Road, Jin Shui District, Zhengzhou 450000, Henan Province, China. lizhihn2009@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Li J, Li H, Run ZC, Wang ZL, Jiang T, An Y, Li Z. RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma. World J Gastrointest Oncol 2022; 14(8): 1574-1584 [PMID: 36160746 DOI: 10.4251/wjgo.v14.i8.1574]
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1574-1584 Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1574
RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma
Jian Li, Huan Li, Zeng-Ci Run, Zhen-Lei Wang, Tao Jiang, Yang An, Zhi Li
Jian Li, Zeng-Ci Run, Zhen-Lei Wang, Zhi Li, Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, Zhengzhou 450000, Henan Province, China
Huan Li, Department of Gastroenterology, Sixth Medical Center of Chinese PLA General Hospital, Beijing 100048, China
Tao Jiang, Medicine Innovation Research Division of Chinese PLA General Hospital, Beijing 100853, China
Yang An, Faculty of Hepato-Pancreato-Biliary Surgery, Sixth Medical Center of Chinese PLA General Hospital, Beijing 100048, China
Author contributions: Li J and Li Z designed the study; Li J and Li H contributed equally to this study; An Y and Li Z are the co-corresponding authors; Run ZC, Wang ZL, Jiang T, and An Y collected the samples; Li J, Li H, An Y performed the research; Li J, Li H and Li Z analyzed the date; Li J wrote the paper; Li J and Li Z revised the manuscript for final submission.
Supported byNational Natural Science Foundation of China, No. 81972010; Science Developing Funds of Navy General Hospital, No. CXPY201810.
Institutional review board statement: The study was reviewed and approved by the Chinese PLA General Hospital Review Board.
Informed consent statement: All study participants or their legal guardian provided written informed consent prior to study enrollment.
Conflict-of-interest statement: We declare that we have no financial or personal relationships with other individuals or organizations that can inappropriately influence our work and that there is no professional or other personal interest of any nature in any product, service and/or company that could be construed as influencing the position presented in or the review of the manuscript.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Corresponding author: Zhi Li, DA, Chief Doctor, Department of General Surgery, Affiliated Tumor Hospital of Zhengzhou University, Henan Tumor Hospital, No. 127 Dong Ming Road, Jin Shui District, Zhengzhou 450000, Henan Province, China. lizhihn2009@163.com
Received: May 26, 2022 Peer-review started: May 26, 2022 First decision: June 21, 2022 Revised: July 2, 2022 Accepted: July 22, 2022 Article in press: July 22, 2022 Published online: August 15, 2022 Processing time: 76 Days and 3.7 Hours
ARTICLE HIGHLIGHTS
Research background
DNA methylation in serum or plasma was demonstrated to be a potential biomarker for cancer detection and prognosis.
Research motivation
More sensitive and accurate methods for detecting methylation in plasma are urgently needed in clinical practice.
Research objectives
In this study, we aimed to evaluate RASSF1A methylation in plasma by digital polymerase chain reaction (PCR) for colorectal cancer (CRC) and hepatocellular carcinoma (HCC).
Research methods
A total of 92 CRC patients, 67 colorectal polyp (CRP) patients, 63 HCC patients, and 66 liver cirrhosis (LC) patients were enrolled. The plasma DNA was detected by digital PCR. The diagnostic value was evaluated by the area under the curve (AUC).
Research results
The DNA methylation rate of RASSF1A in plasma in the CRC group was 2.87 ± 1.80, and that in the CRP group was 1.50 ± 0.64. The AUC of RASSF1A methylation for discriminating the CRC and CRP groups was 0.82 (0.76-0.88). The AUCs of T1, T2, T3 and T4 CRC and CRP were 0.83 (0.72-0.95), 0.87 (0.78-0.95), 0.86 (0.77-0.95), and 0.75 (0.64-0.85), respectively. The DNA methylation rate of RASSF1A in plasma in the HCC group was 4.45 ± 2.93, and that in the LC group was 2.46 ± 2.07. The AUC of RASSF1A methylation for discriminating the HCC and LC groups was 0.70 (0.60-0.79). The AUCs of T1, T2, T3 and T4 HCC and LC were 0.80 (0.61-1.00), 0.74 (0.59-0.88), 0.60 (0.42-0.79), and 0.68 (0.53-0.82), respectively.
Research conclusions
We demonstrate that RASSF1A methylation in plasma detected by digital PCR may be a potential biomarker for CRC and HCC.
Research perspectives
Different methylation detection methods should be compared, and more samples need to be detected.
